As Lilly Korea's Emgality passed the HIRA's Drug Reimbursment Evaluation Committee, discussions on the benefit of the migraine txs are rapidly progressing. Following Emgality, Handok Teva's Ajovy, the same (CGRP) target treatment, is also seeking to enter the benefit.

Reyvow of Ildong Pharmaceutical, which was approved in Korea on the 12th, is also speeding up the payment process through the approval-benefit evaluation linkage system.

On the 12th, the Drug Reimbursment Evaluation Committee of the HIRA held the fifth meeting in 2022 and judged that Lilly's Emgality was eligible for the benefit. Accordingly, Emgality will enter the stage of drug price negotiations with the NHIS.